Sudarshan Pharma Says Proposed 9.5% Stake Acquisition in US Firm Under Due Diligence
New Delhi [India], September 15: Sudarshan Pharma Industries Ltd has provided an update on its proposed acquisition of a 9.5% equity stake i...
New Delhi [India], September 15: Sudarshan Pharma Industries Ltd has provided an update on its proposed acquisition of a 9.5% equity stake in US-based Med Therapy Biotechnology Inc., stating that the transaction is currently under due diligence.
In a regulatory filing dated September 15, the company said the proposal to acquire the 9.5% stake in Med Therapy remains subject to completion of due diligence and confirmation of the decision by Med Therapy’s Board of Directors. The company clarified that the earlier disclosure was only an intimation of the proposal and that the transaction has not yet been completed.